Factors influencing the time to surgery after neoadjuvant chemotherapy in breast cancer patients

• Published in: Archives of gynecology and obstetrics Vol. 301; no. 4; pp. 1055 - 1059
• Main Authors: Müller, Carolin, Juhasz-Böss, Ingolf, Schmidt, Gilda, Jungmann, Peter, Solomayer, Erich-Franz, Breitbach, Georg-Peter, Juhasz-Böss, Stephanie
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2020; Springer Nature B.V
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - surgery; Chemotherapy; Chemotherapy, Adjuvant - methods; Endocrinology; Female; Gynecologic Oncology; Gynecology; Human Genetics; Humans; Medicine; Medicine & Public Health; Middle Aged; Mutation; Obstetrics/Perinatology/Midwifery; Surgery; Time Factors; Treatment Outcome; Young Adult; Neoadjuvant therapy; Delaying factors; Breast cancer; Time to surgery
• ISSN: 0932-0067; 1432-0711; 1432-0711
• DOI: 10.1007/s00404-020-05494-6

Purpose It is suspected that delayed surgery after neoadjuvant chemotherapy (NACT) leads to a worse outcome in breast cancer patients. We therefore evaluated possible influencing factors of the time interval between the end of NACT and surgery. Methods All patients receiving NACT due to newly diagnosed breast cancer from 2015 to 2017 at the Department of Gynecology, Saarland University Medical Center, were included. The time interval between end of NACT and surgery was defined as primary endpoint. Possible delaying factors were investigated: age, study participation, outpatient and inpatient presentations, implants/expander, MRI preoperatively, discontinuation of chemotherapy, and genetic mutations. Results Data of 139 patients was analyzed. Median age was 53 years (22–78). The time interval between end of NACT and surgery was 28 days (9–57). Additional clinical presentations on outpatient basis added 2 days ( p  = 0.002) and on inpatient basis added 7 days to time to surgery ( p  < 0.001). Discontinuation of NACT due to chemotherapy side effects prolonged time to surgery by 8 days ( p  < 0.001), whereas discontinuation due to disease progress did not delay surgery ( p  = 0.6). In contrast, a proven genetic mutation shortened time to surgery by 7 days ( p  < 0.001). Patient’s age, participation in clinical studies, oncoplastic surgery, and preoperative MRI scans did not delay surgery. Conclusion Breast care centers should emphasize a reduction of clinical presentations and a good control of chemotherapy side effects for breast cancer patients to avoid delays of surgery after NACT.